Interpace Biosciences, Inc. (IDXG)
Snapshot
- 1 week
- +10.0%+10.1% vs SPY
- 1 month
- -14.2%-13.4% vs SPY
- Market cap
- $32.5M
- P/E
- 0.2industry 33.3
- P/B
- 1.3
- P/FCF
- 7.9
- EV/EBITDA
- 6.4
- FCF yield
- 12.6%
- Short % float
- 0.0%
- Days to cover
- 1.0
- Short change
- 0.0%
- Consensus
- Buy6 buy · 1 hold · 0 sell
Signal evidence
Peers
| Symbol | Name | Price | Day | Mkt cap | Call | Regime |
|---|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | $173.25 | +2.5% | $23.2B | Locked | Locked |
| NEO | NeoGenomics, Inc. | $16.69 | +0.6% | $2.2B | Locked | Locked |
| PSNL | Personalis, Inc. | $15.88 | +0.2% | $1.7B | Locked | Locked |
| CSTL | Castle Biosciences, Inc. | $33.30 | +0.7% | $1.0B | Locked | Locked |
| MYGN | Myriad Genetics, Inc. | $6.02 | +3.4% | $575.8M | Locked | Locked |
| FLGT | Fulgent Genetics, Inc. | $20.22 | +0.6% | $556.4M | Locked | Locked |
Prediction markets
Kalshi · Polymarket · … linked
Company
Interpace Biosciences, Inc. (IDXG). Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreatic…
- Thomas W. BurnellPresident, Chief Executive Officer & ChairmanUSD 708K
- Christopher McCarthyChief Financial Officer & Chief Operating OfficerUSD 468K
- Sydney D. FinkelsteinChief Pathology Officer
- Patrick KaneVice President & Corporate Controller
- Nicole MassollChief Medical Officer
Snapshot
Price & returns1 month -14.2%
- 1 week
- +10.0%+10.1% vs SPY
- 1 month
- -14.2%-13.4% vs SPY
ValuationP/E 0.2 vs industry 33.3 · market cap $32.5M
- Market cap
- $32.5M
- P/E
- 0.2industry 33.3
- P/B
- 1.3
- P/FCF
- 7.9
- EV/EBITDA
- 6.4
- FCF yield
- 12.6%
Short interest & optionsshort 0.0% of float
- Short % float
- 0.0%
- Days to cover
- 1.0
- Short change
- 0.0%
Street & earnings6 buy · 1 hold · 0 sell6 buy · 1 hold · 0 sell
- Consensus
- Buy6 buy · 1 hold · 0 sell
Signal evidence
Peers
| Symbol | Name | Price | Day | Mkt cap | Call | Regime |
|---|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | $173.25 | +2.5% | $23.2B | Locked | Locked |
| NEO | NeoGenomics, Inc. | $16.69 | +0.6% | $2.2B | Locked | Locked |
| PSNL | Personalis, Inc. | $15.88 | +0.2% | $1.7B | Locked | Locked |
| CSTL | Castle Biosciences, Inc. | $33.30 | +0.7% | $1.0B | Locked | Locked |
| MYGN | Myriad Genetics, Inc. | $6.02 | +3.4% | $575.8M | Locked | Locked |
| FLGT | Fulgent Genetics, Inc. | $20.22 | +0.6% | $556.4M | Locked | Locked |
Prediction markets
Kalshi · Polymarket · … linked
Company
Interpace Biosciences, Inc. (IDXG). Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreatic…
- Thomas W. BurnellPresident, Chief Executive Officer & ChairmanUSD 708K
- Christopher McCarthyChief Financial Officer & Chief Operating OfficerUSD 468K
- Sydney D. FinkelsteinChief Pathology Officer
- Patrick KaneVice President & Corporate Controller
